首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1563381

流感疫苗市场规模、份额、成长分析、按类型、按适应症、按年龄层、按分销管道、按地区 - 行业预测，2024-2031 年

Influenza Vaccine Market Size, Share, Growth Analysis, By Type, By Indication, By Age Group, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月25日 | 出版商:

SkyQuest | 英文 200 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球流感疫苗市场规模为73.9亿美元，从2023年的79.1亿美元成长到2031年的135.7亿美元，预测期（2024-2031）预计复合年增长率为6.98%。

流感疫苗市场对于对抗季节性流感流行和减少其健康影响至关重要。该市场包括为预防各种流感病毒株而开发的各种疫苗，包括季节性流感和大流行性流感。公众对疫苗接种益处的认识不断提高以及全球流感发病率上升推动了市场的成长。各国政府和卫生组织正在推动疫苗宣传活动，以改善公共卫生并降低与流感相关併发症相关的医疗费用。该市场的特点是疫苗开发不断创新，包括推出提供更广泛保护和提高功效的四价和高剂量疫苗。此外，疫苗技术和输送系统的进步也有助于市场扩张。儘管市场成长，市场仍面临疫苗接种犹豫和疫苗分配中的物流问题等挑战。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

GSK plc（UK）
Pfizer Inc.（US）
Vaxess Technologies Inc.（US）
Merck & Co., Inc.（US）
Viatris Inc.（US）
OSIVAX（France）
AstraZeneca（UK）
SINOVAC（China）
CSL Limited（Australia）
Emergent BioSolutions Inc.（US）
Emergex Vaccines（UK）
Sanofi（France）
BIKEN Co., Ltd.（Japan）
Abbott（US）
Altimmune Inc.（US）
Baxter International Inc.（US）
BioDiem Ltd（Australia）
BiondVax Pharmaceuticals Ltd.（Israel）
F. Hoffmann-La Roche Ltd.（Switzerland）
FluGen Inc.（US）
Mitsubishi Chemical Group Corp.（Japan）
Novavax Inc.（US）
Otsuka Holdings Co. Ltd.（Japan）
Shijiazhuang Yiling Pharmaceutical Co., Ltd.（China）
SK Chemicals Co., Ltd.（South Korea）

简介目录

Product Code: SQMIG35B2144

Global Influenza Vaccine Market size was valued at USD 7.39 billion in 2022 and is poised to grow from USD 7.91 billion in 2023 to USD 13.57 billion by 2031, growing at a CAGR of 6.98% in the forecast period (2024-2031).

Influenza vaccine market is vital for combating seasonal flu outbreaks and mitigating their health impacts. This market encompasses a range of vaccines developed to protect against various strains of the influenza virus, including seasonal and pandemic flu. The market's growth is driven by increasing public awareness about the benefits of vaccination and rising incidences of influenza globally. Governments and health organizations promote vaccination campaigns to enhance public health and reduce healthcare costs associated with flu-related complications. The market is characterized by continuous innovation in vaccine development, including the advent of quadrivalent and high-dose vaccines that offer broader protection and improved efficacy. Additionally, advancements in vaccine technologies and delivery systems contribute to the market's expansion. Despite its growth, the market faces challenges such as vaccine hesitancy and logistical issues in vaccine distribution.

Top-down and bottom-up approaches were used to estimate and validate the size of the Influenza Vaccine Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Influenza Vaccine Market Segmental Analysis

Global Influenza Vaccine Market is segmented on the basis of type, indication, route of administration, age group, distribution channel, and region. By type, market is segmented into inactivated, and live attenuated. By indication, market is segmented into quadrivalent, and trivalent. By route od administration, injection, and nasal spray. By age group, market is segmented into pediatric, and adult. By distribution channel, market is segmented into hospital & pharmacies, government & institutional supply, and other. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Influenza Vaccine Market

One significant driver of the influenza vaccine market is the growing awareness and initiatives aimed at increasing vaccination rates. Public health campaigns, government policies, and educational programs have effectively raised awareness about the importance of influenza vaccination in preventing seasonal outbreaks and reducing the burden on healthcare systems. For instance, the World Health Organization (WHO) and national health agencies regularly promote vaccination to protect vulnerable populations, including the elderly, children, and individuals with chronic conditions. These initiatives not only educate the public about the benefits of vaccination but also offer subsidized or free vaccines to increase accessibility. Additionally, healthcare providers play a crucial role in recommending vaccinations and addressing concerns, which further drives vaccine uptake. This increased focus on vaccination contributes to higher immunization rates and drives market growth.

Restraints in the Influenza Vaccine Market

A significant restraint in the influenza vaccine market is vaccine hesitancy, which affects the overall vaccination rates and market growth. Vaccine hesitancy is influenced by various factors, including misinformation about vaccine safety and efficacy, personal beliefs, and concerns about potential side effects. Despite the proven effectiveness of influenza vaccines in preventing flu and reducing severe outcomes, some individuals remain reluctant to receive them due to misconceptions or lack of trust in the healthcare system. This hesitancy can lead to lower vaccination rates and contribute to outbreaks of influenza, undermining public health efforts. Addressing vaccine hesitancy requires targeted education campaigns, transparent communication from health authorities, and improved access to vaccines to build public confidence and ensure higher immunization rates.

Market Trends of the Influenza Vaccine Market

A notable trend in the influenza vaccine market is the continuous innovation in vaccine technologies. Advances in vaccine development are focused on enhancing efficacy, broadening coverage, and improving patient convenience. One such innovation is the development of quadrivalent vaccines, which protect against four different strains of the influenza virus, offering broader protection compared to traditional trivalent vaccines. Additionally, high-dose and adjuvanted vaccines are being introduced to enhance immune responses, particularly in older adults who may have weakened immune systems. The advent of new delivery systems, such as needle-free options and combination vaccines, also contributes to market growth by improving vaccine acceptance and ease of administration. These technological advancements not only aim to increase the effectiveness of influenza vaccines but also to address specific needs of various population groups, thereby driving market expansion and improving overall public health outcomes.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pipeline Analysis
Pricing Analysis

Influenza Vaccine Market, By Type

Market Overview
Inactivated
Live Attenuated

Influenza Vaccine Market, By Indication

Market Overview
Quadrivalent
Trivalent

Influenza Vaccine Market, By Route of Administration

Market Overview
Injection
Nasal Spray

Influenza Vaccine Market, By Age Group

Market Overview
Pediatric
Adult

Influenza Vaccine Market, By Distribution Channel

Market Overview
Hospital & Pharmacies
Government & Institutional Supply
Other

Influenza Vaccine Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

GSK plc (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxess Technologies Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OSIVAX (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SINOVAC (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergex Vaccines (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BIKEN Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altimmune Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioDiem Ltd (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BiondVax Pharmaceuticals Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FluGen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitsubishi Chemical Group Corp. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Holdings Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SK Chemicals Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments